Literature DB >> 32179513

A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma.

Christophe A Girard1, Margaux Lecacheur2, Rania Ben Jouira1, Ilona Berestjuk1, Serena Diazzi1, Virginie Prod'homme3, Aude Mallavialle4, Frédéric Larbret5, Maéva Gesson6, Sébastien Schaub7, Sabrina Pisano8, Stéphane Audebert9, Bernard Mari10, Cédric Gaggioli11, Eleonora Leucci12, Jean-Christophe Marine13, Marcel Deckert4, Sophie Tartare-Deckert14.   

Abstract

Aberrant extracellular matrix (ECM) deposition and stiffening is a physical hallmark of several solid cancers and is associated with therapy failure. BRAF-mutant melanomas treated with BRAF and MEK inhibitors almost invariably develop resistance that is frequently associated with transcriptional reprogramming and a de-differentiated cell state. Melanoma cells secrete their own ECM proteins, an event that is promoted by oncogenic BRAF inhibition. Yet, the contribution of cancer cell-derived ECM and tumor mechanics to drug adaptation and therapy resistance remains poorly understood. Here, we show that melanoma cells can adapt to targeted therapies through a mechanosignaling loop involving the autocrine remodeling of a drug-protective ECM. Analyses revealed that therapy resistant cells associated with a mesenchymal de-differentiated state displayed elevated responsiveness to collagen stiffening and force-mediated ECM remodeling through activation of actin-dependent mechanosensors Yes-associated protein (YAP) and Myocardin-related transcription factor (MRTF). Short-term inhibition of MAPK pathway also induced mechanosignaling associated with deposition and remodeling of an aligned fibrillar matrix. This provided a favored ECM reorganization that promoted tolerance to BRAF inhibition in a YAP and MRTF-dependent manner. Matrix remodeling and tumor stiffening were also observed in vivo upon exposure of BRAF-mutant melanoma cell lines or patient-derived xenograft models to MAPK pathway inhibition. Importantly, pharmacological targeting of YAP reversed treatment-induced excessive collagen deposition, leading to enhancement of BRAF inhibitor efficacy. We conclude that MAPK pathway targeting therapies mechanically reprogram melanoma cells to confer a drug-protective matrix environment. Preventing melanoma cell mechanical reprogramming might be a promising therapeutic strategy for patients on targeted therapies.
Copyright ©2020, American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32179513     DOI: 10.1158/0008-5472.CAN-19-2914

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Harder, better, faster, stronger: biochemistry and biophysics in the immunosurveillance concert.

Authors:  Maria Tello-Lafoz; Miguel M de Jesus; Morgan Huse
Journal:  Trends Immunol       Date:  2021-12-29       Impact factor: 16.687

Review 2.  Mechanical regulation of chromatin and transcription.

Authors:  Sirio Dupont; Sara A Wickström
Journal:  Nat Rev Genet       Date:  2022-05-23       Impact factor: 59.581

3.  3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer.

Authors:  Huan Gao; Qi Tian; Yan Zhou; Lizhe Zhu; Yinliang Lu; Yingying Ma; Jinteng Feng; Yina Jiang; Bo Wang
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

4.  Cell-cell adhesion impacts epithelia response to substrate stiffness: Morphology and gene expression.

Authors:  David Choi; Zachary Gonzalez; Sum Yat Ho; Alexandra Bermudez; Neil Y C Lin
Journal:  Biophys J       Date:  2021-12-02       Impact factor: 3.699

5.  SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas.

Authors:  Eliot Y Zhu; Jesse D Riordan; Marion Vanneste; Michael D Henry; Christopher S Stipp; Adam J Dupuy
Journal:  NPJ Precis Oncol       Date:  2022-10-21

6.  Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment.

Authors:  Christine Lebrun-Frenay; Ilona Berestjuk; Mikael Cohen; Sophie Tartare-Deckert
Journal:  Neurol Ther       Date:  2020-07-25

Review 7.  Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas.

Authors:  Jiri Vachtenheim; Lubica Ondrušová
Journal:  Life (Basel)       Date:  2021-05-05

Review 8.  Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.

Authors:  Veronica Romano; Immacolata Belviso; Alessandro Venuta; Maria Rosaria Ruocco; Stefania Masone; Federica Aliotta; Giuseppe Fiume; Stefania Montagnani; Angelica Avagliano; Alessandro Arcucci
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 9.  Cell Adhesion Molecules in Plasticity and Metastasis.

Authors:  Jessica A Smart; Julia E Oleksak; Edward J Hartsough
Journal:  Mol Cancer Res       Date:  2020-10-01       Impact factor: 6.333

Review 10.  Cancer-Associated Fibroblasts: Understanding Their Heterogeneity.

Authors:  Kévin Louault; Rong-Rong Li; Yves A DeClerck
Journal:  Cancers (Basel)       Date:  2020-10-24       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.